180 Life Sciences Corp Stock Price, News & Analysis

180 Life Sciences Corp. (NASDAQ:ATNF), a biotechnology company transitioning to the iGaming sector, has announced significant enhancements to its legacy intellectual property portfolio through two new patent developments.

The first development is the granting of U.S. Patent No. 12,325,744 B2 by the USPTO, focused on methods for preventing post-operative cognitive decline. This patent, owned by The Kennedy Trust and licensed to 180, covers treatments for reducing cognitive impairment following planned inflammatory triggers like surgery or chemotherapy.

The second development involves a Notice of Allowance from the Canadian Intellectual Property Office for a patent application covering the treatment of localized fibrotic disorders using an IL-33 antagonist. This patent, owned solely by 180, specifically targets conditions like Dupuytren's Disease and Frozen Shoulder.

180 Life Sciences Corp. (NASDAQ:ATNF) has received a Notice of Allowance from the USPTO for a patent application covering a novel method to prevent Post-Operative Cognitive Dysfunction (POCD). The patent focuses on reducing POCD by administering anti-Human tumor necrosis factor (TNF) Alpha monoclonal antibody during surgical procedures.

POCD is a significant complication affecting elderly patients undergoing surgery, manifesting as memory loss, concentration impairment, delirium, and other cognitive issues. The company's method targets inflammatory pathways via ATNF therapy to minimize neuroinflammation post-surgery.

Notably, while this patent strengthens the company's legacy biotechnology portfolio, 180 Life Sciences is currently transitioning its focus to the global iGaming sector, developing online casino and entertainment businesses through its Technology Gaming Platform.

180 Life Sciences has announced a significant share repurchase agreement with Elray Resources and Luxor Capital. The company will acquire and cancel 1,318,000 shares (23.1% of outstanding shares) for $1 million through a structured payment plan: $350,000 directly to Elray and $650,000 to Luxor from future capital raises by April 2026.

The deal includes a Voting Agreement requiring Elray to vote remaining shares according to the Board's recommendations until April 2026, with CEO Blair Jordan holding irrevocable proxy. The agreement features mutual releases, confidentiality obligations, and indemnity protection.

This strategic move aims to reduce dilution and simplify the company's capital structure while preserving cash liquidity. The company plans to focus on monetizing its Technology Gaming Platform through potential online casino acquisitions.

180 Life Sciences Corp. (NASDAQ:ATNF), a biotech company transitioning to international entertainment and iGaming, has announced a $2.9 million registered direct offering and concurrent private placement. The company will sell 1,200,000 common stock shares at $2.41 per share, along with unregistered warrants for an additional 1,200,000 shares. The warrants, exercisable immediately at $2.28 per share, will expire after five and a half years. Maxim Group is serving as the sole placement agent, with the offering expected to close around December 30, 2024.

180 Life Sciences Corp has announced its return to full compliance with Nasdaq Listing Rule 5605(c)(2) following the appointment of Stephen Shoemaker as an independent director and audit committee member. This appointment resolves all previously announced deficiencies in Nasdaq's continued listing requirements.

Interim CEO Blair Jordan confirmed that the company is now focusing on its strategic pivot into the iGaming sector, highlighting the potential of their recently acquired Technology Gaming Platform, particularly in relation to cryptocurrency adoption. The management team and board are aligned on leveraging emerging technologies and market trends in the iGaming industry.

180 Life Sciences Corp (NASDAQ:ATNF) has appointed Stephen Shoemaker to its Board of Directors, effective December 3, 2024. The company, which is transitioning from biotechnology to focus on international entertainment and iGaming, gains Shoemaker's extensive experience in gaming and eSports sectors. As a senior executive, Shoemaker has raised over $2 billion in capital across four companies and has significant experience in scaling high-growth organizations.

At WIN Group, as CEO, Shoemaker led the launch of a licensed iGaming platform that tripled total bet volume in its second month. He also served as CEO of Engine Media Holdings, where he created the first publicly-traded pure-play eSports company. Concurrent with Shoemaker's appointment, Omar Jimenez is stepping down from the Board to focus on his CFO role.

180 Life Sciences Corp (NASDAQ:ATNF) has announced the appointment of Vaclav Vincalek as Senior Technology Consultant to oversee the integration of their recently acquired Gaming Technology Platform. Vincalek, an experienced technologist with expertise in technical leadership and strategy, will work with management to establish the company's online gaming infrastructure. This strategic move represents the company's effort to expand its presence in the gaming industry and enhance its technological capabilities. The integration is expected to strengthen the company's infrastructure and create new growth opportunities.

180 Life Sciences Corp. (NASDAQ:ATNF) has appointed Jay Goodman to its Board of Directors as an independent member and Audit Committee member. Goodman brings over a decade of expertise in SaaS and iGaming industries, with seven years in executive leadership. He currently serves as Sales Director for Asia Pacific and Japan at Docker, Inc. His prior experience includes roles at Confluent, Skywind Games, Dropbox, Hootsuite, and OFX. The appointment aligns with 180's strategy to expand into the online gaming market, according to Interim CEO Blair Jordan.

180 Life Sciences Corp. (NASDAQ:ATNF) announced its strategic entry into the online gaming industry with a newly acquired blockchain-based gaming platform. The company plans to establish blockchain-based B2C online casinos and expand into a B2B model, offering technology solutions for gaming operators worldwide. Key features of the platform include:

1. Blockchain casino operations back-end
2. Seamless blockchain to FIAT exchange technology
3. Blockchain API technology
4. Player account management
5. Loyalty systems for blockchain users
6. Affiliate tracking system

The company aims to launch operations in high-growth international markets, focusing on jurisdictions like Germany, Brazil, India, Canada, and Colombia. 180 Life Sciences Corp. targets having its first online casino fully operational by the end of Q1 2025, subject to funding and successful implementation of its commercialization strategy.